Elevated levels of sHLA-G have been observed in gastric cancer, ovarian cancer, cervical cancer, and endometrial cancer, hinting at the potential of sHLA-G in distinguishing malignant from benign and defining tumor stages [82, 91, 132–137]. This evidence concerns the gene HLA-G and cervical cancer.